Overview

A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants

Status:
Completed
Trial end date:
2021-01-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare two different formulations of mirikizumab in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will also be collected. Participants will remain in the study for about 12 weeks, after receiving study drug.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Mirikizumab